MedTrace Logo

Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator

NCT02798289 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2017-10-25

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to evaluate acute tear production as measured by tear meniscus height (TMH) captured by optical coherence tomography (OCT) after single use of the Oculeve Intranasal Neurostimulator (OIN) in participants with dry eye.

Conditions

  • Dry Eye Syndrome
  • Keratoconjunctivitis Sicca

Interventions

DEVICE

Oculeve Intranasal Neurostimulator

Neurostimulation device

Sponsors & Collaborators

  • Oculeve, Inc.

    lead INDUSTRY

Principal Investigators

  • Neil Friedman, MD · Mid-Peninsula Ophthalmology Medical Group

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02798289 on ClinicalTrials.gov